Tucson, Arizona / May 28, 2025 — Aspiro Therapeutics, a preclinical-stage biopharmaceutical company pioneering the development of groundbreaking, disease-modifying therapies for obstructive lung diseases, today announced its selection to present at the BIO 2025 Startup Stadium, part of the BIO International Convention taking place June 17 to 20 in Boston, Massachusetts. Aspiro will present its lead program on Thursday, June 19, highlighting a novel inhaled peptidomimetic therapy designed to transform treatment for chronic respiratory disease.
Startup Stadium provides a high-visibility platform for emerging biotech companies to share their science with investors, venture firms, and strategic partners. Aspiro was selected for its first-in-class approach, which harnesses the protective properties of CC16, a natural lung protein vital for healthy breathing. The company’s lead therapy is being developed to address the underlying mechanisms of disease progression rather than simply managing symptoms.
“Aspiro is committed to delivering safer, more effective solutions for patients living with obstructive lung disease,” said James Lovgren, CEO and Co-Founder of Aspiro Therapeutics. “We are honored to present at BIO’s Startup Stadium and look forward to connecting with potential partners and investors in Boston.”
Aspiro’s lead candidate is currently in preclinical development. The company’s approach is based on CC16-inspired small peptidomimetics and is aimed at restoring lung function and modifying the course of disease to improve long-term outcomes for patients.
![2025 RIS showcase company_banner-signature-650 x 150 (2)[63]](https://aspirotx.com/wp-content/uploads/elementor/thumbs/2025-RIS-showcase-company_banner-signature-650-x-150-263-r4ct5hpv3cumv4qvdn3anpf886awyr43mq6b3gm03i.jpg "2025 RIS showcase company_banner-signature-650 x 150 (2)[63]")
